Thursday, 3 October, 2019 - 10:53
Winlo joins Emerald Clinics
Medicinal cannabis research company Emerald Clinics has boosted its management team with the appointment of Michael Winlo as chief executive, ahead of an expected IPO later this year.
Emyria (formerly Emerald Clinics) is a Perth-based ASX-listed data-backed drug development and care delivery company.
Emyria uses data sourced from its clinical services subsidiary Emerald Clinics, which was listed on the ASX in 2020 through an IPO.
Rank | Company | 1 Yr | 5 Yr |
---|---|---|---|
1424th | VRX Silica | -45.28% | -12.17% |
1425th | RMA Global | -45.48% | -35.15% |
1426th | Emyria | -45.7% | 0% |
1427th | Strike Resources | -45.75% | -9.14% |
1428th | Next Science | -45.84% | -43.04% |
Rank | Company | # | |
---|---|---|---|
117th | ![]() |
Emyria | $4.82m |
118th | ![]() |
Adveritas | $4.76m |
119th | - | HITIQ | $4.75m |
120th | ![]() |
Harvest Technology Group | $4.38m |
![]() |
NEW ROLE: Michael Winlo, Chief Scientific Officer | 23 Jan 2025 |
![]() |
NEW ROLE: Greg Hutchinson, Executive Chair | 23 Jan 2025 |
![]() |
NEWS: Tagged in Board Moves November 21, 2023 | 21 Nov 2023 |
![]() |
NEW ROLE: Greg Hutchinson, Non-Executive Chair | 21 Nov 2023 |
![]() |
NEWS: Tagged in Board Moves November 13, 2023 | 13 Nov 2023 |
Medicinal cannabis research company Emerald Clinics has boosted its management team with the appointment of Michael Winlo as chief executive, ahead of an expected IPO later this year.
With mainstream acceptance for cannabinoid medicines growing, Emerald Clinics has found value in building clinical evidence of its use.
Perth companies Emerald Clinics and Little Green Pharma are seeking to raise up to $18 million ahead of stock market listings as they pursue very different strategies in the medicinal cannabis market.
The state government has appointed an industry reference group to develop a growth plan for WA’s health and medical life sciences sector to be chaired by Peter Klinken.
Emerald Clinics and Little Green Pharma have both completed their initial public offerings ahead of stock market listings this month, with Emerald getting ready for its ASX debut tomorrow.
COVID-19 has taken a wrecking ball through the IPO market, cutting raisings by 80 per cent, although those that proceeded outperformed other equities.
Perth’s largest drug testing company plans to nearly double capacity as WA attracts attention from global pharmaceutical companies.
The strong growth of the medicinal cannabis industry will need to be supported by research for the sector to take the next step.
A post-pandemic bounce back in initial public offerings could indicate confidence among WA investors.
Our board moves wrap includes Stephen McIntosh, Manuel Ramos, Karen Smith, Tom Wilcox, and Oonagh Malone.
Fifty Perth-based companies and organisations - including education institutions, numerous local startups and not for profits and mining giants have been announced as finalists for the INCITE Awards - WA’s longest running ICT Awards program.
Shares in Perth-based medicinal cannabis aspirant Emyria were up as much as 21 per cent after the business revealed a $5 million backing from Andrew Forrest’s investment business, Tattarang.
Our board moves wrap includes Neville Bassett, Neil Marston, Michele Anderson, Karen Smith, Debra Singh, Toni Thornton, David Foster, Mark Johnson, Gerard McMahon, Neale Edwards, and Matt Briggs.
Andrew Forrest-backed Emyria is slated to start human clinical trials within weeks for a cannabinoid drug to treat psychological distress.
Graham Upson is sharing his knowledge with a company seeking to grow mushrooms for mental health.
A $250 million venture capital initiative launched by the Forrest family seeks to leverage the millions of dollars of health-related R&D funding by governments and bridge the commercialisation 'valley of death' faced by many startups.
The commercial side of life sciences may have reached a critical mass in WA.
Our board moves wrap includes Chris Radin, Sheila Khama, Stirling Ross, Gerry Kaczmarek, Tony Kiernan, Derek Humphry, Dale Richards, Nerida Schmidt, Patricia Farr, Simon Robertson, Susan Park, Peter Webse, ChongTao Xu, Andrew Taplin, Carol Marinkovich, Rowan Harland, Arron Canicais, David Lim, Andrew Woskett, Benjamin Donovan, and Shaun Menezes.
Health tech has taken a front seat in recent months thanks to the combined funding from government and private sectors.
Our board moves wrap includes Jeremy Robinson, Matt Freedman, Michelle Roth, Bruce McFadzean, Mohit Kaushal, Matt Callahan, Simon Linge, and Bruce Munro.
Our board moves wrap includes Alistair Vickery, Stewart Washer, Karen Smith, Tracey Horton, Peter Gundy, Clint Moxham, Carla Healy, Damon Fieldgate, Paul Farrell, and Andrew Brown.
Our board moves wrap includes Luke Meter, YaXi Zhan, Greg Hutchinson, Henry Heng, Colin Moran, Richard Mei, Brett Crowley, and Aldo Miccio.
Access to our data for Emyria is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Emyria is included in 1 list - Public Companies - Industrial WA.
For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.